NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 10.85 against a street estimate of 11.83 — a miss of 8.3%.
with an average price target of ₹1,507.31.
CONFIDENT Cipla delivered sequential growth and higher margins, with India strong and U.S. recovery dependent on Ventolin, Advair and pending launches. Management retained FY27 U.S. run-rate and EBITDA guidance, while investing heavily in pipeline and manufacturing readiness. Q2 FY26 South Africa outperformed its 5% market growth, while emerging markets and Europe faced geopolitical and market-specific headwinds. Analysts focused on the U.S. revenue bridge, launch timing, supply ramp-up, margins, regulatory observations and biosimilar investment. Management emphasized manufacturing readiness, multiple launch pathways and retained guidance. 2026-10-27…
Full summary in the app.
| Holder | Stake |
|---|---|
| Lici Ulip-growth Fund | 9.59% |
| HDFC Mutual Fund - HDFC Focused Fund | 4.03% |
| SBI Elss Tax Saver Fund�� | 3.41% |
| ICICI Prudential Nifty50 Equal Weight Index Fund�� | 2.89% |
| Nippon Life India Trustee Ltd-a/c Nippon India Arb | 2.03% |
| Document | Date |
|---|---|
| Investor presentation · Q1 FY27 CIPLA LTD - Q1FY27 INVESTOR SUMMARY HEADLINE NUMBERS • Total Revenue: INR 7,119 Cr ($162 Mn) – highest-ever quarterly revenue, up 2% YoY • EBITDA: I | 2026-07-23 |
| Quarterly results · Q1 FY27 CIPLA LIMITED – Q1 FY2027 FINANCIAL SUMMARY HEADLINE NUMBERS • Total Revenue from Operations (Consolidated): ₹7,119.28 Crores (Q1 FY2027) vs ₹6,541. | 2026-07-23 |
| Q1 FY27 earnings call DOCUMENT SUMMARY I cannot access or summarize this document. The file you've provided shows an "Access Denied" error from the NSE India archives serv | 2026-07-03 |
| Annual report FY2026 CIPLA LTD. - ANNUAL GENERAL MEETING NOTICE SUMMARY HEADLINE NUMBERS • Final dividend declared: ₹13 per equity share (650% on face value of ₹2) for F | 2026-06-01 |
| Q4 FY26 earnings call CIPLA LIMITED – Q4 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 FY26 quarterly revenue: INR 6,541 crores; full-year FY26 revenue: INR 28,163 crores • | 2026-05-15 |
| Investor presentation · Q4 FY26 CIPLA LTD – Q4 FY26 INVESTOR PRESENTATION SUMMARY HEADLINE NUMBERS • FY26 Total Revenue: INR 28,163 Cr (USD 3.4 Bn); up 2.2% YoY from INR 27,548 Cr | 2026-05-13 |
| Quarterly results · Q4 FY26 CIPLA LIMITED - FINANCIAL RESULTS SUMMARY For FY ended 31st March 2026 --- HEADLINE NUMBERS • Revenue from operations (FY 2026): ₹28,162.59 Crores | 2026-05-13 |
| Q3 FY26 earnings call CIPLA LIMITED Q3 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Quarterly revenue: Rs 7,074 crores, flat year-on-year • EBITDA margin (excluding other inc | 2026-01-27 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹13 / share ex-date Jun 5, 2026 | 2026-06-05 |
| Announcement | Date |
|---|---|
| Merger of Inzpera Healthsciences with company per NCLT order Cipla Limited is acquiring Inzpera Healthsciences Limited through a scheme of amalgamation (absorption), where Inzpera becomes absorbed into Cipla. The National Company Law Tribunal (NCLT) a | 2026-09-03 |
| Enters into venture agreement with Kemwell Biopharma for joint venture Cipla Limited, a major Indian pharmaceutical company, has announced a joint venture (JV) partnership with Kemwell Biopharma Private Limited. Under this agreement, a new joint venture company | 2026-03-02 |
| Acquisition announced by pharmaceutical company Cipla Limited has informed the Exchange about Acquisition | 2025-12-04 |
| Acquisition announced by pharmaceutical company Cipla Limited has informed the Exchange about Acquisition | 2025-11-03 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cipla Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.